A randomised, double-blind, placebo-controlled, multicentre phase I trial investigating the safety of ALK grass tablet in children aged 5-12 years with grass pollen induced rhinoconjunctivitis (with/without asthma)
Latest Information Update: 11 Apr 2022
At a glance
- Drugs Timothy grass pollen allergen extract (Grastek) (Primary)
- Indications Grass pollen hypersensitivity; Rhinoconjunctivitis
- Focus Adverse reactions
- Sponsors ALK-Abello
- 05 May 2006 New trial record.